Skip to main content
SpringerLink
Log in

Risk stratification and prediction of cancer of focal thyroid fluorodeoxyglucose uptake during cancer evaluation

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Background

Focal thyroid incidentaloma by F-18 2-deoxy-2-F18-fluoro-d-glucose (FDG) positron emission tomography (PET) has been reported 1–4% of cancer patients and normal healthy population, with a risk of cancer ranging 14–50%. The aim of this study was to investigate the prevalence of thyroid incidentaloma in F-18 FDG PET/CT and risk of cancer, usefulness of visual and SUVmax and SUVmean differentiating malignant nodules and to define the predictable variables.

Patients and methods

A total 159 patients with focal thyroid FDG incidentaloma during cancer evaluation with non-thyroid cancer were enrolled. After F-18 PET/CT, we analyzed the image visually and obtained semiquantitative indices.

Result

The incidence of focal FDG thyroid incidentaloma is 1.36% and cancer risk is 23.3%. The incidence of focal thyroid FDG uptake was significantly higher in women (2.88 vs. 0.31%; χ 2 = 136.4, p < 0.0001). Malignant thyroid incidentalomas show statistically significant higher value of SUVmax (malignant: median 4.53, range 2.1–12.0; benign: median 3.08, range 1.6–35, p = 0.0093). However, SUVmean have no statistical differences (malignant: median 2.17, range 1.77–3.19; benign: median 2.05, range 1.15–5.77, p = 0.0541). In ROC analyses, the optimal visual grades were >grade 3, and the optimal semiquantitative indices were 4.46 for SUVmax, 2.03 for SUVmean. The visual grade was superior to other variables for the differentiation malignant from benign thyroid incidentalomas. The size and visual grade was the potent predictor by logistic regression analysis.

Conclusion

Focal thyroid FDG incidentalomas in non-thyroid cancer patients during evaluation have a high risk of malignancy. The size and visual grade are potential predictors for malignant thyroid incidentaloma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med. 1997;126:226–31.

    CAS  PubMed  Google Scholar 

  2. Hedegus L. Clinical practice: the thyroid nodule. N Engl J Med. 2004;351:1764–71.

    Article  Google Scholar 

  3. Burguera B, Gharib H. Thyroid incidentalomas prevalence, diagnosis, significance, and management. Endocrinol Metab Clin North Am. 2000;29:187–203.

    Article  CAS  PubMed  Google Scholar 

  4. Oriuchi N, Higuchi T, Ishikita T, Miyakubo M, Hanaoka H, Iida Y, et al. Present role and future prospects of positron emission tomography in clinical oncology. Cancer Sci. 2006;97:1291–7.

    Article  CAS  PubMed  Google Scholar 

  5. Sobhani I, Tiret E, Lebtahi R, Aparicio T, Itti E, Montravers F, et al. Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer. 2008;98:875–80.

    Article  CAS  PubMed  Google Scholar 

  6. Kasper B, Dietrich S, Dimitrakopoulou-Strauss A, Strauss LG, Haberkorn U, Ho AD, et al. Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomography. Onkologie. 2008;31:107–12.

    Article  PubMed  Google Scholar 

  7. Wakabayashi H, Nishiyama Y, Otani T, Sano T, Yachida S, Okano K, et al. Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer. World J Gastroenterol. 2008;14:64–9.

    Article  PubMed  Google Scholar 

  8. Loft A, Berthelsen AK, Roed H, Ottosen C, Lundvall L, Knudsen J, et al. The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol. 2007;106:29–34.

    Article  PubMed  Google Scholar 

  9. Geus-Oei LF, Oyen WJ. Predictive and prognostic value of FDG-PET. Cancer Imaging. 2008;8:70–80.

    Article  PubMed  Google Scholar 

  10. Hutchings M, Specht L. PET/CT in the management of haematological malignancies. Eur J Haematol. 2008;80:369–80.

    Article  PubMed  Google Scholar 

  11. de Geus-Oei LF, van der Heijden HF, Corstens FH, Oyen WJ. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer. 2007;110:1654–64.

    Article  PubMed  Google Scholar 

  12. Nam SY, Roh JL, Kim JS, Lee JH, Choi SH, Kim SY. Focal uptake of 18F-fluorodeoxyglucose by thyroid in patients with nonthyroidal head and neck cancers. Clin Endocrinol. 2007;67:135–9.

    Article  Google Scholar 

  13. Kim TY, Kim WB, Ryu JS, Gong G, Hong SJ, Shong YK. 18F-fluorodeoxyglucose uptake in thyroid from positron emission tomography (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope. 2005;115:1074–8.

    Article  PubMed  Google Scholar 

  14. Kurata S, Ishibashi M, Hiromatsu Y, Kaida H, Miyake I, Uchida M, et al. Diffuse and diffuse-plus-focal uptake in the thyroid gland identified by using FDG PET: prevalence of thyroid cancer and Hashimoto`s thyroiditis. Ann Nucl Med. 2007;21:325–30.

    Article  PubMed  Google Scholar 

  15. Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Collins DA, et al. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl Med Comm. 2007;28:373–81.

    Article  Google Scholar 

  16. Kang KW, Kim SK, Kang HS, Lee ES, Kim JS, Lee IG, et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab. 2003;88:4100–4.

    Article  CAS  PubMed  Google Scholar 

  17. van den Bruel A, Maes A, de Potter T, Mortelmans L, Drijkoningen M, Van Damme B, et al. Clinical relevance of thyroid fluorodeoxyglucose whole body positron emission tomography incidentaloma. J Clin Endocrinol Metab. 2002;87:1517–20.

    Article  PubMed  Google Scholar 

  18. Cohen MS, Arslan N, Dehdashti F, Doherty GM, Lairmore TC, Brunt MB, et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose positron emission tomography. Surgery. 2001;130:941–6.

    Article  CAS  PubMed  Google Scholar 

  19. Choi JY, Lee KS, Kim HJ, Shim YM, Kwon OJ, Park K, et al. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization. J Nucl Med. 2006;47:609–15.

    PubMed  Google Scholar 

  20. Yi JG, Marom EM, Truong MT, Macapinlac HA, Gladish GW, Sabloff BS, et al. Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer. Radiology. 2006;236:271–5.

    Article  Google Scholar 

  21. Gough J, Scott-Coombes D, Fausto Palazzo F. Thyroid incidentaloma: an evidence-based assessment of management strategy. World J Surg. 2008 (epub ahead of print). doi:10.1007/s00268-008-9503-2.

  22. Yasuda S, Ide M. PET and cancer screening. Ann Nucl Med. 2005;19:167–77.

    Article  PubMed  Google Scholar 

  23. Kim JM, Ryu JS, Kim TY, Kim WB, Kwon GY, Gong G, et al. 18F-fluorodeoxyglucose positron emission tomography does not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm. J Clin Endocrinol Metab. 2007;92:1630–4.

    Article  CAS  PubMed  Google Scholar 

  24. Sebastianes FM, Cerci JJ, Zanoni PH, Soares J Jr, Chibana LK, Tomimori EK, et al. Role of 18F-fluorodeoxyglucose positron emission tomography in preoperative assessment of cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab. 2007;92:4485–8.

    Article  CAS  PubMed  Google Scholar 

  25. Liu Y. Clinical significance of thyroid uptake in F18-fluorodeoxyglucose positron emission tomography. Ann Nucl Med. 2009;23:17–23.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Pusan National University Hospital, Busan, 602-739, Republic of Korea

    Bo Hyun Kim, Min A. Na & Yong-Ki Kim

  2. Department of Nuclear Medicine, Pusan National University Hospital, 1-10, Ami-dong, Seo-gu, Busan, 602-739, Republic of Korea

    In Joo Kim & Seong-Jang Kim

  3. Medical Research Institute, Pusan National University Hospital, Busan, 602-739, Republic of Korea

    In Joo Kim & Seong-Jang Kim

Authors
  1. Bo Hyun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Min A. Na
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. In Joo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seong-Jang Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yong-Ki Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seong-Jang Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, B.H., Na, M.A., Kim, I.J. et al. Risk stratification and prediction of cancer of focal thyroid fluorodeoxyglucose uptake during cancer evaluation. Ann Nucl Med 24, 721–728 (2010). https://doi.org/10.1007/s12149-010-0414-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-010-0414-6

Keywords

Search

Navigation